Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial

• Published in: BMC cancer Vol. 20; no. 1; pp. 342 - 8
• Main Authors: Ali, Arwa, Dumbrava, Monica, Riddell, Kylie, Stewart, Nina, Ward, Robyn, Ibrahim, Ahmed K., Chin, Melvin
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 22.04.2020; BioMed Central; BMC
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; BRAF-inhibitors; Brain research; Cancer metastasis; Care and treatment; Clinical trials; Computer industry; Dabrafenib; Duration of Therapy; Female; Follow-Up Studies; Humans; Imidazoles - therapeutic use; Lesions; Male; Medical care quality; Medical imaging equipment; Medical research; Melanoma; Melanoma - drug therapy; Melanoma - genetics; Melanoma - pathology; Metastases; Metastasis; Metastatic melanoma; Middle Aged; Multivariate analysis; Mutation; Oximes - therapeutic use; Patients; Predictive biomarkers; Prognosis; Proto-Oncogene Proteins B-raf - genetics; RECIST-base assessment; Regression analysis; Retrospective Studies; Software; Solid tumors; Studies; Survival; Survival Rate; Treatment duration; Tumor Burden - drug effects; Tumor volume; Tumors; United States; United Kingdom > UK; Wales; Metastatic melanoma; Tumor volume; Treatment duration; Predictive biomarkers; BRAF-inhibitors; RECIST-base assessment

Planar-based measurements of lesions in metastatic melanoma have limitations in estimating tumor burden of a patient and in predicting response to treatment. Volumetric imaging might add predictive value to Response criteria in Solid Tumor (RECIST)-measurement. Based on clinical observations, we exp...